​The work presented here is from the ongoing characterization of our lead compound, KMN-159, which shows high selectivity for EP₄ binding, excellent potency for EP4 activation, potent stimulation of osteoblastic differentiation in unfractionated bone marrow cells (BMCs), and remarkable chemical stability.

Do you have a question or comment for the presenter? Let us know.

To cite this poster: Owen, T., Wei, S., Birmingham, K., et al. Biochemical and molecular characterization of the osteoblastic differentiation of rat bone marrow stem cells treated with KMN-159, a novel selective EP₄ prostaglandin receptor agonist. Poster presented at: ASBMR 2019 Annual Meeting; September 20-23, 2019; Orlando, FL.